🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Xencor, Inc. XNCR R2KR3KPHARMA

Healthcare · Biotechnology · United States
https://www.xencor.com
Company Profile ↓
$26.61
+244.69% 1Y
Mkt Cap$1.98B
P/E-12.32
P/B2.99
52W High$29.30
52W Low$7.44
Book Value$6.96
EPS (TTM)$-2.16

Company Overview

Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered antibodies for the treatment of cancer and autoimmune diseases. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, and neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It also develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; XmAb942, which is in clinical development for patients with Crohn's disease and ulcerative colitis; Plamotamab, a bispecific T-cell, which is in Phase Ib study to treat rheumatoid arthritis; and XmAb657 for patients with idiopathic inflammatory myopathies. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat metastatic castration-resistant prostate cancer; Obexelimab, an antibody to treat patients with autoimmune diseases; Tobevibart, a treatment for chronic hepatitis Delta; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Novartis, an antibody drug candidate that uses XmAb Fc technologies; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.

Why Investors Should Care

Conservative Balance Sheet

Carries low leverage with a debt-to-equity ratio of 0.34.

Recent Developments

  • Dec 2025 Revenue of $125.58M (+13.7% YoY); net profit $-91.92M.
  • Trailing 12 Months Year-on-year growth — revenue +17.5%.
  • 5-Year Trend Long-term compounding — revenue CAGR 1.6%.

Growth & Price Performance

Compounded Sales Growth

5 Years:1.58%
1 Year:17.50%

Stock Price Performance

1 Year:+244.69%
6 Months:+135.07%
3 Months:+126.08%
1 Month:+33.05%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Bullish
52-Week Range 88% of range
$7.44 $29.30
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMAAbove
  • RSI (14)58.92 · Neutral
Price Performance
1M+33.05%
3M+126.08%
6M+135.07%
1Y+244.69%

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • In a confirmed uptrend (50-DMA above 200-DMA).

CONS

No notable concerns flagged.

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
-12.32
Industry PE
25.17
Forward P/E
-7.60
PEG Ratio
-
Book Value
$6.96
Price to Book
2.99
P/S
14.74
EV/EBITDA
-6.09
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
1.58%
Profit 5Y
-
Revenue (YoY)
17.50%
Earnings (YoY)
-

Profitability & Returns

ROCE
-22.77%
ROE
-29.07%
ROA
-16.84%
Profit Margin
-
Op Margin
-72.37%
Gross Margin
-
EPS (Latest Qtr)
$-0.29
EPS (TTM)
$-2.16

Balance Sheet & Liquidity

Debt/Equity
0.34
Quick Ratio
6.09
Current Ratio
6.39
Debt
$170.11M
Total Assets
$724.96M
Current Assets
$482.86M
Working Capital
$503.91M

Ownership

Promoter Holding
1.22%
Chg in Prom Hold
-0.00%
FII / Inst Holding
114.78%
Chg in FII Hold
0.01%

Financial Snapshot

Enterprise Value
$1.98B
Total Revenue (TTM)
$104.97M
EBITDA
$-205.90M
Free Cash Flow
$-94.54M
Operating Cash Flow
$-205.81M
Shares Outstanding
74.35M
Gross Margin
-
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 XNCR Xencor, Inc. R2KR3KPHARMA 26.61 -12.32 $1.98B 0.00% -22.77% -29.07% 1.58% -
2 LLY Eli Lilly and Company SPXR3KPHARMA 1,149.36 38.57 $1.02T 0.58% - 102.29% 7.20% 11.41%
3 JNJ Johnson & Johnson SPXR3KPHARMA 275.23 31.97 $663.28B 2.09% 14.88% 25.74% 2.43% 4.76%
4 ABBV AbbVie Inc. SPXR3KPHARMA 256.46 72.45 $453.19B 2.84% 10.47% -129.24% 1.75% -29.06%
5 MRK Merck & Co., Inc. SPXR3KPHARMA 150.33 120.26 $371.29B 2.65% - 34.70% 5.64% 10.01%
6 UNH UnitedHealth Group Incorporated SPXR3KPHARMA 397.14 25.54 $356.47B 2.33% 9.74% 14.15% 10.40% 5.43%
7 NVS Novartis AG PHARMA 159.99 24.20 $304.10B 3.03% 21.09% 30.35% 9.25% 26.22%
8 AZN AstraZeneca PLC NDXPHARMA 162.70 24.36 $252.33B 1.98% 15.97% 21.96% 9.82% 45.96%
9 AMGN Amgen Inc. NDXSPXR3KPHARMA 437.23 27.14 $235.98B 2.49% 13.95% 91.47% 5.51% 5.55%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Revenue ------3.50M12.50M-30.15M--29.04M11.56M111.94M19.48M21.76M3.52M32.38M13.09M35.37M41.85M33.97M67.45M19.68M85.50M30.18M27.30M18.96M45.52M59.16M16.00M23.91M17.80M32.73M43.61M21.00M28.24M4.52M51.22M
Cost of Revenue ----------------------------------------
Gross Profit ----------------------------------------
Operating Expenses ----------------------------------75.92M76.78M68.52M81.86M82.38M-
Operating Income -10.31M7.44M-6.73M48.56M-9.26M-10.03M-16.36M-8.51M-23.58M5.33M-30.65M-28.29M651.00K-21.08M78.24M-19.57M-14.28M-30.57M-8.78M-37.60M-16.72M-13.70M-15.67M9.09M-41.30M26.47M-28.00M-38.35M-60.74M-26.00M-18.27M-54.66M-55.37M-55.20M-43.18M-33.17M-47.52M-53.63M-77.86M-37.07M
EBITDA -----------------------------------36.91M-20.18M4.23M5.67M-121.37M-
Interest Expense ----------------------------------8.66M8.24M7.67M7.35M4.70M-
Pretax Income -----------------------------------48.27M-31.07M-6.03M-4.27M-128.64M-
Tax Provision ----------------------------------367.00K-250.00K02.39M280.00K-
Net Income -10.04M7.76M-6.40M47.16M-8.08M-9.06M-15.47M-7.72M-22.65M7.37M-29.49M-25.87M3.15M-18.20M80.05M-16.03M-10.22M-26.91M-8.07M-35.02M-12.55M-13.69M-2.49M52.25M-40.19M23.59M-33.98M-32.76M-60.76M-21.95M-24.27M-73.44M-67.34M-46.29M-48.42M-30.82M-6.03M-6.65M-128.92M-21.73M
Diluted EPS -0.250.19-0.161.13-0.20-0.21-0.33-0.17-0.480.15-0.62-0.460.05-0.321.38-0.28-0.18-0.47-0.14-0.61-0.22-0.24-0.040.87-0.690.39-0.57-0.55-1.02-0.37-0.40-1.20-1.09-0.72-0.66-0.41-0.08-0.09-1.71-0.29
R&D Expense 10.58M-10.04M14.41M14.07M-15.05M16.92M19.41M-26.09M23.33M20.95M-28.18M33.30M29.77M-33.94M43.46M44.45M-41.41M49.50M50.61M47.76M47.08M53.27M65.55M60.06M64.94M56.87M61.53M58.23M58.58M61.66M54.37M-64.67M71.91M

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue ----109.02M46.15M40.60M156.70M122.69M275.11M164.58M174.62M110.49M125.58M
Cost of Revenue --------------
Gross Profit --------------
Operating Expenses ----------247.05M306.98M288.90M303.08M
Operating Income -6.23M-10.52M-16.46M-18.34M44.04M-43.12M-79.37M13.82M-76.80M43.77M-82.47M-132.36M-178.41M-177.50M
EBITDA -----------45.70M-101.96M-186.17M-47.19M
Interest Expense ----------13.00K6.18M36.64M31.93M
Pretax Income -----------54.51M-119.63M-234.92M-89.63M
Tax Provision ----------673.00K13.66M1.62M2.50M
Net Income -8.59M-60.26M-16.42M-17.59M45.12M-38.49M-70.41M26.88M-69.33M82.63M-55.18M-133.13M-232.62M-91.92M
Diluted EPS -118.86-3.85-0.52-0.451.07-0.82-1.310.46-1.211.37-0.93-2.08-3.58-1.24
R&D Expense 12.67M17.00M18.52M34.14M51.87M71.77M97.50M118.59M169.80M192.51M199.56M253.60M227.69M239.43M

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --87.31M67.82M206.91M428.56M390.20M576.73M670.25M703.24M-846.27M965.13M951.95M875.50M
Current Assets -----------675.34M635.60M577.60M599.82M
Cash & Equivalents 14.54M2.31M77.97M54.65M12.59M14.53M16.53M26.25M50.31M163.54M-53.94M53.79M40.88M54.07M
Inventory ---------------
Receivables -----------29.00M23.74M60.85M29.30M
Total Liabilities --13.78M8.53M44.48M114.61M73.74M55.05M77.05M130.80M-118.77M303.05M277.92M239.91M
Current Liabilities --7.48M6.20M43.43M106.29M72.65M53.85M66.56M121.06M-63.84M73.92M87.43M95.91M
Long Term Debt ------------161.77M115.16M76.48M
Total Debt -----------59.63M251.94M231.95M187.75M
Total Equity -157.70M-166.27M73.53M59.29M162.43M337.93M316.46M521.68M593.20M572.44M-727.50M661.75M677.61M635.59M
Shares Outstanding -----------60.00M61.00M70.26M71.87M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow ---26.67M95.24M-33.60M-79.76M64.37M-5.00M-24.48M-77.93M-202.19M-135.12M
Investing Cash Flow ----185.11M-214.27M31.86M-164.77M-50.97M100.19M--119.72M-111.06M-7.87M139.99M
Financing Cash Flow ---116.38M120.97M3.73M254.24M10.66M18.04M-5.70M189.22M197.15M8.23M
Capital Expenditure -41.00K-136.00K-780.00K-1.93M-1.51M-5.31M-7.21M-7.35M-10.54M--43.40M-21.25M-9.51M-3.15M
Free Cash Flow ---24.74M93.73M-38.91M-86.97M57.02M-15.54M--18.92M-99.18M-211.70M-138.27M
Net Change in Cash -----------89.54M228.00K-12.91M13.10M

Ratios (Annual)

Figures in %.

Metric Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % --------------
Operating Margin % ----40.4%-93.4%-195.5%8.8%-62.6%15.9%-50.1%-75.8%-161.5%-141.4%
Net Margin % ----41.4%-83.4%-173.4%17.2%-56.5%30.0%-33.5%-76.2%-210.5%-73.2%
ROE % 5.2%-81.9%-27.7%-10.8%13.4%-12.2%-13.5%4.5%-12.1%--7.6%-20.1%-34.3%-14.5%
ROCE % --13.2%-26.7%-11.2%13.7%-13.6%-15.2%2.3%-13.2%--10.5%-14.9%-20.6%-22.8%

Shareholding Pattern

Insiders
1.22%
Institutions
114.78%
Public Float
116.19%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 18.36% 13.65M $355.75M
2 Primecap Management Company 13.69% 10.18M $265.33M
3 BVF Inc. 9.59% 7.13M $185.90M
4 RTW Investments LP 9.12% 6.78M $176.62M
5 RA Capital Management, L.P. 7.09% 5.27M $137.45M
6 State Street Corporation 6.66% 4.95M $129.10M
7 Vanguard Capital Management LLC 4.41% 3.28M $85.45M
8 TCG Crossover Management, LLC 3.30% 2.45M $63.90M
9 Price (T.Rowe) Associates Inc 3.17% 2.36M $61.41M
10 Vanguard Portfolio Management LLC 2.98% 2.22M $57.74M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for XNCR

Yahoo Finance Wed, 02 Sep 2026

Xencor to Present at the 2026 Cantor Global Healthcare Conference

PASADENA, Calif., September 02, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will …

Yahoo Finance Sat, 08 Aug 2026

How Investors May Respond To Xencor (XNCR) Narrowing Quarterly Losses Amid Deeper First‑Half Deficit

Xencor, Inc. has reported its second-quarter 2026 results, with net loss improving to US$21.73 million versus US$30.83 million a year earlier, while basic and diluted loss per share from continuing operations narrowed to US$0.29 from US$0.4…

Yahoo Finance Wed, 05 Aug 2026

Xencor (XNCR) Reports Q2 Loss, Beats Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of +64.63% and +337.04%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Yahoo Finance Mon, 20 Jul 2026

Xencor (XNCR) Soars 16.9%: Is Further Upside Left in the Stock?

Xencor (XNCR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.…

Yahoo Finance Fri, 17 Jul 2026

Xencor Announces Proffered Paper Oral Presentation at ESMO 2026 for Phase 1 Clinical Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

PASADENA, Calif., July 17, 2026--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that results from a Phase 1 study …

Yahoo Finance Sun, 14 Jun 2026

Xencor (XNCR) Stock Draws Fresh Price Target Split As Pipeline Progress Meets Caution

Xencor’s latest research update includes a US$1 increase in the stock’s price target, while the model’s fair value anchor of US$28.50 stays in place. Bullish analysts view this higher target as a sign that updated work still supports upside…

XNCR — Frequently Asked Questions

What is the current share price of Xencor, Inc. (XNCR)?

As of 2026-09-07 16:24 PDT, Xencor, Inc. (XNCR) trades at $26.61 on NasdaqGM. Its 52-week range is $7.44 to $29.30.

What is the market capitalisation of XNCR?

Xencor, Inc. (XNCR) has a market capitalisation of $1.98B on NasdaqGM.

What is the P/E ratio of XNCR?

XNCR trades at a trailing price-to-earnings (P/E) ratio of -12.32. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 2.99.

What is the return on equity (ROE) of XNCR?

XNCR has a return on equity (ROE) of -29.07%. Its return on capital employed (ROCE) is -22.77%.

Is XNCR a good stock to buy?

This page provides a data-driven analysis of Xencor, Inc. (XNCR), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space